Boston Scientific Corporation (NYSE:BSX) Receives $93.91 Average PT from Brokerages

Boston Scientific Corporation (NYSE:BSX) has been assigned an average rating of “Moderate Buy” from the twenty-six brokerages that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, twenty-two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $93.9130.

Several analysts recently issued reports on the company. Morgan Stanley decreased their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Truist Financial cut their price objective on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. BTIG Research reduced their price objective on shares of Boston Scientific from $90.00 to $80.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Mizuho lowered their target price on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Finally, Canaccord Genuity Group dropped their target price on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, April 23rd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter valued at approximately $26,000. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares in the last quarter. Financial Consulate Inc. bought a new stake in Boston Scientific in the 3rd quarter worth approximately $25,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Finally, United Community Bank boosted its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 1.1%

Shares of Boston Scientific stock opened at $56.62 on Friday. Boston Scientific has a fifty-two week low of $54.98 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.08 and a current ratio of 1.90. The company has a market capitalization of $84.15 billion, a P/E ratio of 23.69, a P/E/G ratio of 1.03 and a beta of 0.62. The company has a fifty day moving average of $65.95 and a 200 day moving average of $83.68.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts anticipate that Boston Scientific will post 3.38 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.